-
1 Comment
Harvard Bioscience, Inc is currently in a long term uptrend where the price is trading 51.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Harvard Bioscience, Inc's total revenue rose by 0.0% to $31M since the same quarter in the previous year.
Its net income has dropped by 211.8% to $-615K since the same quarter in the previous year.
Finally, its free cash flow grew by 35.0% to $2M since the same quarter in the previous year.
Based on the above factors, Harvard Bioscience, Inc gets an overall score of 4/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US4169061052 |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
Beta | 1.47 |
---|---|
Market Cap | 17M |
PE Ratio | None |
Target Price | 4.5 |
Dividend Yield | None |
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HBIO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025